Welcome to our dedicated page for iTonic Holdings SEC filings (Ticker: ITOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iTonic Holdings Ltd filings document foreign-issuer current reports on its brachytherapy healthcare-solutions business, corporate events and listed-company status. The company's Form 6-K disclosures include press-release exhibits, Nasdaq minimum bid price compliance matters, and descriptions of its operating subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., and lead treatment-planning product.
The filing record also covers material-event disclosures, material agreements, capital-structure matters, governance topics, and operating and financial results. These disclosures connect the company's public reporting to its Class A ordinary shares, healthcare-technology operations and corporate obligations as a listed issuer.
iTonic Holdings Ltd reported a board change, with independent director Bin Wu resigning effective June 18, 2026, for personal reasons and without any disagreement over operations, policies, or practices. On the same date, Kun Yang was appointed as a new independent director and joined the Audit, Corporate Governance and Nominating, and Compensation Committees, becoming chair of the Corporate Governance and Nominating Committee. The company notes that Kun Yang meets Nasdaq and SEC independence requirements and has entered into a director agreement and an indemnification agreement with the company.
iTonic Holdings Ltd completed a new private share sale to bring in fresh capital. After mutually terminating a prior March 2026 subscription agreement, the company entered into new Subscription Agreements on April 16, 2026 for a private placement of 100,000,000 Class A ordinary shares at US$0.20 per share, for aggregate gross proceeds of approximately US$20,000,000.
The April 2026 private placement closed the same day, and iTonic issued 100,000,000 Class A ordinary shares to participating investors. These new shares are subject to a six-month lock-up period from the date of issuance, limiting immediate resale. The report also states that its contents are incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements.
iTonic Holdings Ltd received a 180-day extension from Nasdaq, until October 19, 2026, to regain compliance with Nasdaq’s minimum closing bid price requirement under Listing Rule 5550(a)(2). The company previously exhausted an initial 180-day compliance period that ended on April 20, 2026.
If iTonic does not meet the minimum bid price rule by the new deadline, Nasdaq may delist its Class A ordinary shares. iTonic could then request a review of any delisting determination by a Nasdaq Hearings Panel. The company continues to describe itself as a healthcare solution provider focused on brachytherapy treatment planning systems.
iTonic Holdings Ltd director and CEO Zhang Jianfei has filed an initial statement of ownership. The filing shows direct ownership of 33,346 Class A Ordinary Shares. It also reports indirect ownership of 7,668,000 Class B Ordinary Shares held through ZJW (BVI) LTD, where Zhang is the sole shareholder and director. No new purchases or sales are reported; this document mainly establishes Zhang’s status as a major shareholder and executive of iTonic Holdings.
iTonic Holdings Ltd filed an amended Form 20-F mainly to correct the date on Marcum Asia CPAs LLP’s audit report; no other disclosures were changed, although new CEO and CFO certifications were included.
For 2025, iTonic reported revenue of $523,031 and a net loss of $5,098,384, driven by sharp increases in general and administrative and research and development expenses. The auditor and management highlight substantial doubt about the company’s ability to continue as a going concern, noting operating losses, negative operating cash flow of $3,231,427 and the need for additional equity or debt financing to fund operations.
Total assets were $9,096,296 at year-end 2025, including newly recognized goodwill of $1,955,683 and customer-relationship intangibles of $2,414,357 from acquisitions. Cash and cash equivalents fell to $1,490,129 from $6,159,823 as the company invested in short-term investments, acquisitions and operations. Class A ordinary shares outstanding increased to 9,382,000, partly reflecting a 2,800,000-share-based payment in 2025 on top of the 2024 IPO of 2,250,000 Class A shares.
iTonic Holdings Ltd, a Cayman Islands company with operating subsidiary Beijing Feitian, files its annual Form 20-F covering the year ended December 31, 2025. The business focuses on brachytherapy treatment planning software and related medical auxiliary supplies for cancer care in China.
All revenue and operations are in the PRC, so results depend heavily on China’s economic conditions, healthcare policies and medical device regulations. The report emphasizes reliance on multiple PRC licenses and production/operation permits, foreign-exchange and dividend remittance controls, evolving cybersecurity and data rules, and potential PRC tax-residency and withholding tax exposure. It also highlights rising labor and social-benefit costs, stricter employment compliance, and uncertainties around foreign investment, M&A and overseas listings rules that could affect future financing and expansion.
iTonic Holdings Ltd has agreed to a March 2026 private placement of 100,000,000 Class A ordinary shares at US$0.20 per share, for aggregate gross proceeds of about US$20,000,000 to the company. The transaction is expected to close in April 2026, subject to the conditions in the subscription agreement.
The new shares will be subject to a six-month lock-up period from issuance, limiting immediate resale. This report is also incorporated by reference into iTonic’s existing Form S-8 and effective Form F-3 registration statements.
iTonic Holdings Ltd director Zhang Pengfei filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. This filing does not report any stock purchases, sales, option exercises, or other transactions; it simply establishes Zhang’s status as a reporting director at iTonic Holdings.
iTonic Holdings Ltd executive Li Zhixin, the company’s CFO, has filed an initial Form 3 as an officer of the company. The provided data does not show any insider transactions or derivative positions, indicating this filing functions mainly as a baseline ownership disclosure.